CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 2, 2023 and accepted by EDGAR at Aug 2, 2023, 06:36 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $88.92bn | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $174.20bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $53.54bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $104.99bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2023-04-01 to 2023-06-30 | $3.23bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | $6.68bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $686.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $1.27bn | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $656.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $1.39bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | $1.90bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | $4.04bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | $1.48 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | $3.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | $1.48 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | $3.15 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 1,287,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 1,289,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $13.35bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $1.57bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2023-01-01 to 2023-06-30 | $1.57bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months2023-01-01 to 2023-06-30 | $2.02bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-06-30 | $13.81bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $67.76bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $250.07bn | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $79.21bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $177.07bn | us-gaap:Liabilities |
| Short-term borrowings | At period end2023-06-30 | $1.00bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2023-06-30 | $72.73bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-23-000033. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.